1. Home
  2. EURK vs CNTB Comparison

EURK vs CNTB Comparison

Compare EURK & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EURK
  • CNTB
  • Stock Information
  • Founded
  • EURK 2023
  • CNTB 2012
  • Country
  • EURK Cayman Islands
  • CNTB United States
  • Employees
  • EURK N/A
  • CNTB N/A
  • Industry
  • EURK
  • CNTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • EURK
  • CNTB Health Care
  • Exchange
  • EURK NYSE
  • CNTB Nasdaq
  • Market Cap
  • EURK 77.0M
  • CNTB 65.5M
  • IPO Year
  • EURK 2024
  • CNTB 2021
  • Fundamental
  • Price
  • EURK $10.10
  • CNTB $0.99
  • Analyst Decision
  • EURK
  • CNTB Strong Buy
  • Analyst Count
  • EURK 0
  • CNTB 1
  • Target Price
  • EURK N/A
  • CNTB $8.00
  • AVG Volume (30 Days)
  • EURK 11.7K
  • CNTB 27.1K
  • Earning Date
  • EURK 01-01-0001
  • CNTB 09-05-2024
  • Dividend Yield
  • EURK N/A
  • CNTB N/A
  • EPS Growth
  • EURK N/A
  • CNTB N/A
  • EPS
  • EURK N/A
  • CNTB N/A
  • Revenue
  • EURK N/A
  • CNTB $24,116,000.00
  • Revenue This Year
  • EURK N/A
  • CNTB N/A
  • Revenue Next Year
  • EURK N/A
  • CNTB $63.90
  • P/E Ratio
  • EURK N/A
  • CNTB N/A
  • Revenue Growth
  • EURK N/A
  • CNTB N/A
  • 52 Week Low
  • EURK $10.03
  • CNTB $0.68
  • 52 Week High
  • EURK $10.11
  • CNTB $2.84
  • Technical
  • Relative Strength Index (RSI)
  • EURK N/A
  • CNTB 33.74
  • Support Level
  • EURK N/A
  • CNTB $1.00
  • Resistance Level
  • EURK N/A
  • CNTB $1.09
  • Average True Range (ATR)
  • EURK 0.00
  • CNTB 0.09
  • MACD
  • EURK 0.00
  • CNTB -0.02
  • Stochastic Oscillator
  • EURK 0.00
  • CNTB 4.85

About EURK EUREKA ACQUISITION CORP

Eureka Acquisition Corp is a newly incorporated blank check company.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: